Excited to make it to the cover of @NatureRevCancer (December Issue) with our review on the Molecular and Immunological drivers of ADCs!
🔦 Time to shed some light on this complex chemo delivery mechanism 🎯
Read it here: nature.com/articles/s41568-0…
What happens to an ADC after its infusion? How does it interact with tumor & immune cells, what causes response & resistance? Take a deep dive in the molecular world of ADCs though our last review, led by @AlfredZippelius and published in @NatureRevCancer. nature.com/articles/s41568-0…
Would you prefer to lead a lab alone or together with a science buddy? How interesting would be a research institute where joint labs are the standard?!
Excited to share that our story on PGE2-mediated control of NK cell metastasis surveillance in lung tissue is now published in @CellReports
🤝 Thanks to the many great colleagues who helped conduct this study!
👏Congratulations to first author @AMPedde!
cell.com/cell-reports/fullte…
.@LurieCancer’s 2024 Translational Research in Malignancies Symposium was a great success! Thank you to all of today’s speakers for their insights focused on resistance to cancer treatment. View the topics here: cancer.northwestern.edu/docs…
Great work by Ronja Wieboldt and Natalia Mantuano in our lab @DepBiomedicine . They show that myeloid-derived suppressors are inhibiting efficient anti-tumor immunity by secreting CCL2 induced by sialic acid-Siglec interactions.
#glycotimerdcu.be/dAt5I
Our latest story is out in @CellPressImmunity today!! We show that Stat5 opposes Tox and rewires exhausted CD8s towards more durably protective effector-like states. Shout out to my co-authors, @parkerici and @EJohnWherry
Key take-home messages in the 🧵⬇️
cell.com/immunity/ppt/S1074-…
SNSF Starting Grants Call 2024
The call is aimed at researchers who intended to apply for an #ERCStartingGrant in 2023 to conduct an independent scientific project and lead a research team in Switzerland. Submission deadline: 1 February 2024
sohub.io/01rm